Summary Slide.png (72.1 kB)

Implementation of Empagliflozin in Patients With Diabetes Mellitus Type 2 and Established Cardiovascular Disease – Estimation of Five-Year Survival and Costs in Sweden

Download (72.1 kB)
media
posted on 05.10.2020 by Lars Bernfort, Magnus Husberg, Ann-Britt Wiréhn, Ulf Rosenqvist, Staffan Gustavsson, Kristina Karlsdotter, Lars-Åke Levin

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2020.

History

Exports